ENTPD1 and neoplasm: It can be hypothesized that inhibitors targeting CD39 or CD73 may suppress tumor dormancy by preventing the accumulation of extracellular adenosine, thereby restoring the pro-inflammatory functions of immune cells within the tumor microenvironment.